Population-Based Incidence of Infectious Mononucleosis and Related Hospitalizations: 2010 Through 2021
- PMID: 40057874
- PMCID: PMC12136997
- DOI: 10.1016/j.mayocp.2024.09.017
Population-Based Incidence of Infectious Mononucleosis and Related Hospitalizations: 2010 Through 2021
Abstract
Objective: To determine whether the risks of infectious mononucleosis (IM) and serious IM outcomes are changing over time.
Patients and methods: Individuals with a diagnosis of IM and hospitalizations due to IM were identified among persons residing in an Upper Midwest region between January 1, 2010, and December 31, 2021, using the Rochester Epidemiology Project. Infectious mononucleosis rates were calculated assuming the entire population between 2010 and 2021 was at risk, and IM-associated hospitalization rates were calculated among everyone with a diagnosis of IM. Poisson regression was used to test trends and estimate incidence and hospitalization rate ratios.
Results: We identified 5334 individuals with IM; the overall IM rate was 60.60 per 100,000 person-years (95% CI, 58.98 to 62.25). Rates were highest in females, individuals of White race, those with non-Hispanic ethnicity, and individuals 15 to 19 years old (all P<.05). Infectious mononucleosis rates decreased significantly over time among all age groups (all tests for trend, P<.05). Overall, 234 individuals (4.3%) were hospitalized with IM (43.87 per 1000 persons with IM; 95% CI, 38.43 to 49.87), and hospitalization rates among those with IM increased over time (test for trend, P<.05). Individuals younger than 10 years, those 20 years or older, and individuals of Hispanic ethnicity had increased risk for IM-associated hospitalization (all adjusted P<.05).
Conclusion: Although rates of IM diagnosis have decreased over time, risk of hospitalization in individuals with IM has increased. Age and ethnicity increase the risk of hospitalization due to IM.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Drs St. Sauver and Jacobson, Ms Weston, and Ms Fan received grant funding from Moderna, Inc, to conduct the study. Dr Buck is an employee of Moderna, Inc, and has equity interest in Moderna, Inc. Dr Hall was an employee of Moderna, Inc at the time this study was conducted.
Figures
Similar articles
-
Emergency department visits and hospitalizations attributable to recent Epstein-Barr virus infection.Curr Med Res Opin. 2024 Nov;40(11):1885-1891. doi: 10.1080/03007995.2024.2408465. Epub 2024 Oct 15. Curr Med Res Opin. 2024. PMID: 39405254
-
Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom.BMC Public Health. 2020 Jun 12;20(1):912. doi: 10.1186/s12889-020-09049-x. BMC Public Health. 2020. PMID: 32532296 Free PMC article.
-
Rates of Influenza-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death by Race and Ethnicity in the United States From 2009 to 2019.JAMA Netw Open. 2021 Aug 2;4(8):e2121880. doi: 10.1001/jamanetworkopen.2021.21880. JAMA Netw Open. 2021. PMID: 34427679 Free PMC article.
-
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].Epidemiol Prev. 2023 Jan-Apr;47(1-2 Suppl 1):1-286. doi: 10.19191/EP23.1-2-S1.003. Epidemiol Prev. 2023. PMID: 36825373 Italian.
-
Infectious mononucleosis in young children.Am J Emerg Med. 1995 Jul;13(4):438-40. doi: 10.1016/0735-6757(95)90135-3. Am J Emerg Med. 1995. PMID: 7605534 Review.
References
-
- Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92. - PubMed
-
- Rea TD, Russo JE, Katon W, Ashley RL, Buchwald DS. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14(4):234–242. - PubMed
-
- Kap EJ, Konrad M, Kostev K. Clinical characteristics and sick leave associated with infectious mononucleosis in a real-world setting in Germany. Int J Clin Pract. 2021;75(10):e14690. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical